Japanese pharmaceutical company developing drugs in psychiatry/neurology, oncology and regenerative medicine.
Japanese pharmaceutical company developing drugs in psychiatry/neurology, oncology and regenerative medicine.
Earns from prescription drugs sold in Japan and, through its US arm, North America. Its former top seller in the US, Latuda for schizophrenia and bipolar disorder, lost patent protection in 2023, forcing a restructuring around newer products such as Orgovyx and Myfembree.
In one line: A mid-size Japanese pharma like a smaller Otsuka.
Moat: narrow (IP / patents, regulatory licence). Patent-protected drugs generate returns until patent expiry/generic competition, typical for branded pharma.
Headquarters: Osaka, Japan · Founded: 1897 · Employees: 3,123
Size Sumitomo Pharma (4506.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $5.33B, the 231st largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,894 on 18 Nov 2026.
Performance Over six months the shares gained 10.8%, against +2.9% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 10.7% over the last twelve months (peer median +15.3%); the operating margin is 9.6% (peer median 20.6%).
Valuation It trades at 8.6× forward earnings against a peer median of 26.6× (3rd cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is -3%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.7 points above its cost of capital (5.0% WACC).
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥493B | ¥453B | ¥399B | ¥315B | ¥556B |
| Revenue growth | — | +14% | +27% | -43% | — |
| Gross profit | ¥262B | ¥240B | ¥225B | ¥157B | ¥343B |
| EBITDA | ¥67.6B | ¥73.1B | ¥48.0B | ¥36.3B | ¥52.5B |
| Net income | ¥46.2B | ¥107B | ¥23.6B | -¥315B | -¥74.5B |
| Free cash flow | ¥67.5B | ¥67.1B | ¥8.00B | -¥253B | ¥3.47B |
| Capital expenditure | ¥4.70B | ¥7.31B | ¥13.0B | ¥15.7B | ¥12.7B |
| Total debt | ¥140B | ¥224B | ¥314B | ¥428B | ¥346B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sumitomo Pharma 4506.T | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% |
| Otsuka Hldgs 4578.T | $39.9B | +9% | +11% | 18% | 16.8× | 1.6% |
| Eisai 4523.T | $9.36B | +11% | +11% | 6% | 26.6× | 10.7% |
| Astellas Pharma 4503.T | $31.4B | +17% | +19% | 23% | 12.9× | -9.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4506.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.2% | -2.1% | 9th highest of 21 |
| 6-month return | +10.8% | +2.9% | 8th highest of 21 |
| Distance from 52-week high | -42.4% | -27.9% | 6th lowest of 21 |
| Revenue growth (TTM) | +10.7% | +15.3% | 7th lowest of 19 |
| Operating margin | 9.6% | 20.6% | 5th lowest of 19 |
| Forward P/E | 8.6× | 26.6× | 3rd cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 1.7% | 6.6% | 6th least demanding of 16 |
| Growth delivered (Del g) | -2.6% | +13.3% | lowest of 16 |
| Hurdle (Req g minus delivered) | +4.2 pp | -4.5 pp | 5th most demanding of 16 |
| ROIC minus cost of capital | +1.7 pp | +3.8 pp | 7th lowest of 16 |
| EV / EBITDA | 13.5× | 21.5× | 3rd cheapest of 11 |
| Net debt / EBITDA | 0.9× | -0.7× | 3rd most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% | +519.6% |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% | +192.5% |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 25.8× | n/a | n/a |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% | +12.2% |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% | +13.3% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% | +10.0% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% | +3.0% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% | +19.9% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% | +5.5% |
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 27.3× | 57.7% | +7.5% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% | +12.7% |
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% | +13.9% |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | n/a | n/a | n/a |
| RemeGen 9995.HK | Hong Kong | $6.07B | -28% | +293% | 61% | 6.3× | -6.8% | +57.9% |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |